Hormone Receptor Assays: Clinical Usefulness in the Management of Carcinoma of the Breast

References

• Beatson G. T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896b; 2(104)162
   Google Scholar
• Boyd S. On oophorectomy in cancer of the breast. Br. Med. J. 1900; 2: 1161
   Google Scholar
• Thompson A. Analysis of cases in which oophorectomy was performed for inoperable carcinoma of the breast. Br. Med. J. 1902; 2: 1538
   Google Scholar
• Lett H. An analysis of 99 cases of inoperable Carcinoma of the breast treated by oophorectomy. Lancer 1905; I: 227
   Google Scholar
• Thayssen V. E. The influence of castration by roentgen on carcinoma of the breast. Acta Radiol. 1948; 29: 189
   Web of Science ®Google Scholar
• Block G. E., Vial A. B., Pullen F. W. Estrogen excretion following operative and irradiation castration in case of mammary cancer. Surgery 1958; 43: 415
   Google Scholar
• Lathrop A. E. C., Loeb L. Further investigations on the origin of tumors in mice. If. On the part played by internal secretion in the spontaneous development of tumors. J. Cancer Res. 1916; 1: 1
   PubMedGoogle Scholar
• Lacassagne A. Apparition de cancers de la mamelle chez le souris male, sourmise à des injections de folliculine. C. R. Acad. Sci. 1932; 195: 630
   Google Scholar
• Cook J. W., Dodds E. C., Hewett C. L. A synthetic oestrus-exciting compound. Nature (London) 1933; 131: 56
   Google Scholar
• Dodds E. C., Lawson W. Synthetic oestrogenic agents without the phenanthrene nucleus. Nature (London) 1936; 137: 996
   Google Scholar
• Campbell N. R., Dodds E. C., Lawson W. Oestrogenic activity of dianol, a dimeride p-propenylphenol. Nature (London) 1938; 141: 78
   Google Scholar
• Campbell N. R., Dodds E. C., Lawson W. Oestrogenic activity of anol: a highly active phenol isolated from the byproducts. Nature (London) 1938; 142: 78
   Google Scholar
• Dodds E. C., Goldberg L., Lawson W., Robinson R. Oestrogenic activity of certain synthetic compounds. Nature (London) 1938; 141: 247
   Google Scholar
• Dodds E. C., Lawson W., Noble R. L. Biological effects of the synthetic oestrogenic substance 4:4' dihydroxy-α:β diethlstilbene. Lancet 1938; 1: 1389
   Google Scholar
• Lacassagne A. Apparition d'adénocarcinomes mammaires chez des souís males traiées par une substance oestrogéne synthetique. C. R. Seances Soc. Biol. Paris 1938; 129: 641
   Google Scholar
• Haddow A., Watkinson J. M., Paterson E. Influence of synthetic oestrogens upon advanced malignant disease. Br. Med. J. 1944; 3: 393
   Google Scholar
• Walpole A. L., Paterson E. Synthetic oestrogens in mammary cancer. Lancet 1949; 2: 783
   Google Scholar
• Huggins C., Bergenstal D. M. Inhibition of human mammary and prostatic cancer by adrenalectomy. Cancer Res. 1952; 12: 134
   PubMed Web of Science ®Google Scholar
• Huggins C., Dao T. L. Y. Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast. JAMA 1953; 151: 1388
   PubMed Web of Science ®Google Scholar
• Huggins C., Dao T. L. Y. Characteristics of adrenal-dependent mammary cancers. Ann. Surg. 1954; 140: 497
   Google Scholar
• Dao T. L. Y. Estrogen excretion in women with mammary cancer before and after adrenalectomy. Science 1953; 118: 21
   Google Scholar
• Pearson O. H., West D. C., Hollander V. P., Treves N. E. Evaluation of endocrine therapy for advanced breast cancer. JAMA 1954; 154: 234
   PubMed Web of Science ®Google Scholar
• Smith O. W., Emerson K. Urinary estrogens and related compounds in postmenopausal women with mammary cancer: effect of cortisone treatment. Proc. Soc. Exp. Biol. Med. 1954; 85: 264
   Google Scholar
• Luft R., Olivecrona H. Hypophysectomy in man: experience in metastatic cancer of the breast. Cancer 1955; 8: 261
   PubMed Web of Science ®Google Scholar
• Pearson O. H., Li M. C., Maclean J. P., Lipsett M. B., West C. D. Management of metastatic mammary cancer. JAMA 1955; 159: 1701
   Google Scholar
• Twombly D. J., Schoenewaldt E. F. Tissue localization and excretion routes of radioactive diethylstilbestrol. Cancer 1951; 4: 296
   PubMed Web of Science ®Google Scholar
• Hanahan D. J., Daskalskis E. G., Edwards T., Dauben H. J. The metabolic pattern of 14C-diethylstilbestrol. Endocrinology 1953; 53: 163
   PubMed Web of Science ®Google Scholar
• Dodds E. C., Folley S. J., Glascock R. F., Lawson W. The excretion of microgram doses of hexestrol by rabbits and rats. Biochem. J. 1958; 68: 161
   Google Scholar
• Glascock R. F., Hoekstra W. G. Selective accumulation of tritium-labeled hexoestrol by the reproductive organs of immature female goats and sheep. Biochem. J. 1959; 72: 673
   PubMed Web of Science ®Google Scholar
• Jensen E. V., Jacobson H. I. Basic guides to the mechanism of estrogen action. Recent Prog. Horm. Res. 1962; 18: 387
   Google Scholar
• Cantarow A., Stasney J., Paschkis K. E. The influence of sex hormones on mammary tumors induced by 2-acetaminofluorene. Cancer Res. 1948; 8: 412
   Google Scholar
• Shay H., Aegerta E. A., Gruenstein M., Koncrov S. A. Development of adenocarcinoma of the breast in the Wistar rat following the gastric instillation of methylcholanthrene. J. Natl. Cancer Inst. 1949; 10: 255
   Google Scholar
• Shay H., Harris C., Gruenstein M. Influence of sex hormones on the incidence and form of tumors produced in male or female rats by gastric instillation of methylcholanthrene. J. Natl. Cancer Inst. 1952; 13: 307
   PubMed Web of Science ®Google Scholar
• Huggins C., Briziarelli G., Sutton H. Rapid induction of mammary carcinoma in the rat and the influence of hormones on the tumors. J. Exp. Med. 1959; 109: 25
   PubMed Web of Science ®Google Scholar
• Dao T. L., Sutherland H. Mammary carcinogenesis by 3-methylcholanthrene. 1. Hormonal aspects in tumor induction and growth. J. Natl. Cancer Insr. 1959; 23: 567
   Google Scholar
• Geyer R. P., Bryant J. E., Bleische V. R., Peirce E. M., Stare F. J. Effect of dose and hormones on tumor production in rats given emulsified 9, 10-dimethyl-l,2-benzanthracene intravenously. Cancer Res. 1953; 13: 503
   Google Scholar
• Huggins C., Grand L. C., Brillantes F. B. Mammary cancer induced by a single feeding of polynuclear hydrocarbons and its suppresion. Nature (London) 1961; 189: 204
   PubMed Web of Science ®Google Scholar
• King R. J. B., Cowan D. M., Inman D. R. The uptake of [6,7-3H]oestradiol by dimethylbenzanthracene-induced rat mammary tumors. J. Endocrinol. 1965; 32: 83
   Google Scholar
• King R. J. B., Gordon J., Cowan D. M., Inman D. R. The intranuclear localization of [6,7-3H]oestradiol-17β in dimethylbenzanthracene-induced rat mammary adenocarcinoma and other tissues. J. Endocrinol. 1966; 36: 136
   Google Scholar
• Sutherland R. L., Jordan V. C. Non-steroidal Antioestrogens: Molecular Pharmacology and Antitumour Activity. Academic Press, Sydney, Australia 1981
   Google Scholar
• Jordan V. C. Biochemical pharmacology of antiestrogen action. Pharmacol. Rev. 1984; 36: 245
   PubMed Web of Science ®Google Scholar
• Estrogen/Antiestrogen Action and Breast Cancer Therapy, V. C. Jordan. University of Wisconsin Press, Madison 1986
   Google Scholar
• Mobbs B. J. The uptake of tritiated oestradiol by dimethylbenzanthracene-induced mammary tumors of the rat. J. Endocrinol. 1966; 36: 409
   Google Scholar
• Folca P. J., Glascock R. F., Irvin W. T. Studies with tritium-labelled hexoestrol in advanced breast cancer. Lancet 1961; 2: 796
   PubMed Web of Science ®Google Scholar
• Talwar G. P., Segal S. J., Evans A., Davidson O. W. The binding of estradiol in the uterus: a mechanism for depression of RNA synthesis. Proc. Natl. Acad. Sci. USA 1964; 52: 1059
   Google Scholar
• Noteboom W. D., Gorski J. Stereospecific binding of estrogens in the rat uterus. Arch. Biochem. Biophys. 1965; 111: 559
   PubMed Web of Science ®Google Scholar
• Toft D., Gorski J. A receptor molecule for estrogen isolated from rat uterus and preliminary characterization. Proc. Natl. Acad. Sci. USA 1966; 55: 1574
   PubMed Web of Science ®Google Scholar
• Toft D., Shyamala G., Gorski J. A receptor molecule for estrogens studies using a cell-free system. Proc. Natl. Acad. Sci. USA 1967; 57: 1740
   PubMed Web of Science ®Google Scholar
• Jensen E. V., Numata M., Brecher P. I., De Sombre E. R. Hormone-receptor interactions as a guide to biochemical mechanism. The Biochemistry of Steroid Hormone Action, R. M. S. Smellie. Academic Press, London 1971; 133
   Google Scholar
• Gorski J., Toft D., Shyamala G., Smith D., Notides A. Hormone receptors: studies on the interaction of estrogen with the uterus. Recent Prog. Horm. Res. 1968; 24: 45
   PubMedGoogle Scholar
• Jensen E. V., Suzuki T., Kawashima T., Stumpf W. E., Jungblut P. W., De Sombre E. R. A two-step mechanism for the interaction of estradiol with rat uterus. Proc. Natl. Acad. Sci. USA 1968; 59: 632
   PubMed Web of Science ®Google Scholar
• Rochefort H., Baulieu E. E. New in vitro studies of estradiol binding in castrated rat uterus. Endocrinology 1968; 84: 108
   Google Scholar
• Korenman S. G., Rao B. R. Reversible disaggregation of the cytosol binding protein of uterine cytosol. Proc. Narl. Acud. Sci. USA 1968; 61: 1028
   Google Scholar
• Erdos T. Properties of a uterine oestradiol receptor. Biochem. Biophys. Res. Cornmun. 1968; 32: 338
   PubMedGoogle Scholar
• Jensen E. V., Hurst D. J., De Sombre E. R., Jungblut P. W. Sulfhydryl groups and estradiol-receptor interaction. Science 1967; 158: 385
   PubMedGoogle Scholar
• Tate A. C., Jordan V. C. The estrogen receptor. Principles of Receptorology, M. K. Agarwal. Walter de Gruyter, Berlin 1983; 381
   Google Scholar
• Stancel G. M., Leung K. M. T., Gorski J. Estrogen receptors in the rat uterus. Multiple forms produced by concentration-dependent aggregation. Biochemistry 1973; 12: 2130
   Google Scholar
• Giannopoulos G., Gorski J. Estrogen-binding protein of the rat uterus. J. Biol. Chem. 1971; 246: 2530
   Google Scholar
• Stancel G. M., Leung K. M. T., Gorski J. Estrogen receptors in the rat uterus. Relationship between cytoplasmic and nuclear forms of the estrogen binding protein. Biochemistry 1973; 12: 2137
   PubMed Web of Science ®Google Scholar
• Catelli M. G., Binart N., Jung-Testas I., Renoit J. M., Baulieu E. E., Feramisco J. R., Welch W. J. The common 90-kd protein component of nontransformed “8S” steroid receptors is a heat-shock protein. EMBO J. 1985; 4: 3131
   PubMed Web of Science ®Google Scholar
• Garcia T., Buchou T., Renoir J.-M., Mester J., Baulieu E. E. A protein kinase copurified with chick oviduct progestrone receptor. Biochemistry 1986; 25: 7939
   Google Scholar
• Ziemiecki A., Catelli M.-G., Joab I., Moncharmont B. Association of the heat shock protein HS90 with steroid hormone receptors and tyrosine Kinase oncogene products. Biochem. Biophys. Res. Comm. 1986; 138: 1298
   PubMed Web of Science ®Google Scholar
• Coffer A. I., Lewis K. M., Brockas A. J., King R. J. B. Monoclonal antibodies against a component related to soluble estrogen receptor. Cancer Res. 1985; 45: 3686
   PubMed Web of Science ®Google Scholar
• Coffer A. I., Spiller G. H., Lewis K. M., King R. J. B. Immunoradiometric studies with monoclonal antibody against a component related to human estrogen receptor. Cancer Res. 1985; 45: 3694
   Google Scholar
• King R. J. B., Coffer A. I. The generation of antibodies against partially purified estradiol receptor from human myometrium. Estrogen/Antiestrogen Action and Breast Cancer Therapy., V. C. Jordan. University of Wisconsin Press, Madison 1986; 375
   Google Scholar
• Jensen E. V., Suzuki T., Numata M., Smith S., De Sombre E. R. Estrogen binding substances of target tissue. Steroids 1969; 13: 417
   PubMed Web of Science ®Google Scholar
• Honwitz K. B., Mc Guire W. L. Estrogen control of progesterone receptor in human breast cancer. J. Biol. Chem. 1978; 253: 2223
   Google Scholar
• Horwitz K. B., Mc Guire W. L. Nuclear mechanisms of estrogen action. J. Biol. Chem. 1978; 253: 8185
   PubMed Web of Science ®Google Scholar
• Horwitz K. B., Koseki Y., Mc Guire W. L. Estrogen control of progesterone receptor in human breast cancer. Role of estradiol and antiestrogen. Endocrinology 1978; 103: 1742
   PubMed Web of Science ®Google Scholar
• Horwitz K. B., Mc Guire W. L. Actinomycin D prevents nuclear processing of estrogen receptors. J. Biol. Chem. 1978; 253: 6319
   PubMedGoogle Scholar
• Monsma F. J., Jr., Katzenellenbogen B. S., Miller M. A., Ziegler Y. S., Katzenellenbogen J. A. Characterization of the estrogen receptor and its dynamics in MCF-7 breast cancer cells using a covalently-attaching antiestrogen. Endocrinology 1984; 115: 143
   PubMed Web of Science ®Google Scholar
• Eckert R. L., Mullick A., Rorke E. A., Katzenellenbogen B. S. Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by density shift technique. Endocrinology 1984; 114: 629
   PubMed Web of Science ®Google Scholar
• Kassis J. A., Gorski J. Estrogen receptor replenishment—evidence for receptor recycling. J. Biol. Chem. 1981; 256: 7378
   Google Scholar
• Linkie D. M. Estrogen receptors in different target tissues: similarities of form—dissimilarities of transformation. Endocrinology 1977; 101: 1862
   Google Scholar
• Linkie D. M., Siiteri P. K. A re-examination of the interaction of estradiol with target cell receptors. J. Steroid Biochem. 1978; 9: 1071
   Google Scholar
• Zava D. T., Mc Guire W. L. Estrogen receptors. Unoccupied sites in nuclei of a breast tumor cell line. J. Biol. Chem. 1977; 252: 3703
   Google Scholar
• Sheridan P. J., Anselmo V. C., Buchanan J. M., Martin P. M. Equilibrium. The intracellular distribution of steroid receptors. Nature (London) 1979; 282: 579
   Google Scholar
• Carlson R. A., Gorski J. Characterization of a unique population of unfilled estrogen-binding sites associated with the nuclear fraction of immature rat uteri. Endocrinology 1980; 106: 1776
   Google Scholar
• Martin P. M., Sheridan P. M. Towards a new model for the mechanism of action of steroids. J. Steroid Biochem. 1982; 16: 215
   PubMedGoogle Scholar
• Jordan V. C., Tate A. C., Lyman S. D., Gosden B., Wolf M., Bain R. R., Welshons W. V. Rat uterine growth and induction of progesterone receptor without estrogen receptor translocation. Endocrinology 1985; 116: 1845
   Google Scholar
• Greene G. L., Fitch F. W., Jensen E. V. Monoclonal antibodies to estrophilin: probes for the study of estrogen receptors. Proc. Natl. Acad. Sci. USA 1980; 77: 157
   PubMed Web of Science ®Google Scholar
• Greene G. L., Fitch F. W., Jensen E. V. Monoclonal antibodies to human estrogen receptors. Proc. Natl. Acad. Sci. USA 1980; 77: 5115
   PubMed Web of Science ®Google Scholar
• Greene G. L., Jensen E. V. Monoclonal antibodies as probes for estrogen receptor detection and characterization. J. Steroid Biochem. 1982; 16: 353
   PubMedGoogle Scholar
• King W. J., Greene G. L. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature (London) 1984; 307: 745
   PubMed Web of Science ®Google Scholar
• Press M. F., Greene G. L. An immunocytochemical method for demonstrating estrogen receptor in human uterus using monoclonal antibodies to human estrophilin. Lab. Invest. 1984; 50: 480
   PubMed Web of Science ®Google Scholar
• Press M. F., Nousek-Goebl N. A., Greene G. L. Immunoelectron microscopic localization of estrogen receptor with monoclonal estrophilin antibodies. J. Histochem. Cytochem. 1985; 33: 915
   PubMed Web of Science ®Google Scholar
• Welshons W. V., Jordan V. C. Heterogeneity of nuclear steroid hormone receptors with an emphasis on unfilled receptor sites. Steroid Hormone Receptors: Their Intracellular Localization, C. R. Clark. Ellis Horwood, ChichesterEngland 1987; 128
   Google Scholar
• Carter S. B. Effects of cytochalasins on mammalian cells. Nature (London) 1967; 213: 261
   PubMed Web of Science ®Google Scholar
• Herrick G., Spears B. B., Veomett G. Intracellular localization of mouse DNA polymerase α. Proc. Natl. Acad. Sci. USA 1976; 72: 1136
   Google Scholar
• Welshons W. V., Lieberman M. E., Gorski J. Nuclear localization of unoccupied oestrogen receptors. nature (London) 1984; 307: 747
   PubMed Web of Science ®Google Scholar
• Welshons W. V., Jordan V. C. Estrogen receptor distribution in breast cancer cell lines. Proc. Am. Assoc. Cancer Res. 1986; 892, Abstr.
   Google Scholar
• Soule H. D., Vasquez J., Long A., Albert S., Brennan M. J. Human cell line from pleural effusion derived from breast carcinoma. J. Natl. Cancer Inst. 1973; 51: 1409
   PubMed Web of Science ®Google Scholar
• Brooks S. C., Locke E. R., Soule H. D. Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J. Biol. Chem. 1973; 248: 6251
   PubMed Web of Science ®Google Scholar
• Keydar I., Chen L., Karby S., Weiss F. R., Delarea J., Radu M., Chaitcick S., Brenner H. J. Establishment and characterization of a cell line of human breast carcinoma origin. Eur. J. Cancer Clin. Oncol. 1979; 15: 659
   Google Scholar
• Lieberman M. E., Maurer R. A., Gorski J. Estrogen control of prolactin synthesis in vitro. Proc. Natl. Acad. Sci. USA 1978; 75: 5946
   Google Scholar
• Lieberman M. E., Jordan V. C., Fritsch M., Santos M. A., Gorski J. Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro. J. Biol. Chem. 1983; 258: 4734
   PubMed Web of Science ®Google Scholar
• Shafie S. M. Estrogen and the growth of breast cancer: new evidence suggests indirect action. Science 1980; 209: 701
   PubMedGoogle Scholar
• Huseby R. A., Moloney T. M., McGrath C. M. Evidence for a direct growth stimulating effect of estradiol on human MCF-7 cells in vivo. Cancer Res. 1984; 44: 2654
   PubMed Web of Science ®Google Scholar
• Sonnenschein C., Papendorp J. T., Soto A. M. Estrogenic effect of tamoxifen and its derivatives on the proliferation of MCF-7 human breast cancer cells. Life Sci. 1985; 37: 387
   PubMedGoogle Scholar
• Lippman M. E., Bolan G., Huff K. The effects of estrogens and antiestrogens on hormoneresponsive human breast cancer in long-term tissue culture. Cancer Res. 1976; 36: 4595
   PubMed Web of Science ®Google Scholar
• Berthois Y., Katzenellenbogen J. A., Katzenellenbogen B. S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl. Acad. Sci. USA 1986; 83: 2496
   PubMed Web of Science ®Google Scholar
• Welshons W. V., Jordan V. C. Adaption of estrogen-dependent MCF-7 cells to low estrogen (Phenol red-free) culture. Eur. J. Cancer Clin. Oncol. 1987; 23: 1935
   PubMedGoogle Scholar
• Sporn M. B., Todaro G. J. Autocrine secretion and malignant transformation of cells. N. Engl. J. Med. 1980; 303: 878
   PubMed Web of Science ®Google Scholar
• Sporn M. B., Roberts A. B. Autocrine growth factors and cancer. Nature (London) 1985; 313: 745
   PubMed Web of Science ®Google Scholar
• Marquardt H., Hunkapiller M. W., Hood L. E., Todaro G. J. Rat transforming growth factor Type 1: structure and relation to epidermal growth factor. Science. 1984; 223: 1079
   PubMed Web of Science ®Google Scholar
• Tam J. P., Marquardt H., Rosberger D. F., Wong T. W., Todaro G. J. Synthesis of biologically active transforming growth factor. I. Nature (London) 1984; 309: 376
   PubMed Web of Science ®Google Scholar
• Dickson R. B., Huff K. K., Spenser E. M., Lippman M. E. Induction of epidermal growth factor related polypeptides by 17β-estradiol in MCF-7 human breast cancer cells. Endocrinology 1986; 118: 138
   PubMed Web of Science ®Google Scholar
• Dickson R. B., Mc Manaway M., Lippman M. E. Estrogen-induced growth factors of breast cancer cells partially replace estrogen to promote tumor growth. Science 1986; 232: 1540
   PubMed Web of Science ®Google Scholar
• Dickson R. B., Kasid A., Huff K. K., Bates S. E., Knabbe C., Bronzert D., Gelman E. P., Lippman M. E. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17β-estradiol and v-rasH oncogene. Proc. Natl. Acad. Sci. USA 1987; 84: 837
   PubMed Web of Science ®Google Scholar
• Knabbe C., Lippman M. E., Wakefield L. M., Flanders K. C., Kasid A., Derynck R., Dickson R. B. Evidence that transforming growth factor β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417
   PubMed Web of Science ®Google Scholar
• Bronzert D., Siverman S., Lippman M. E. Estrogen inhibition of a Mr 39,000 glycoprotein by human breast cancer cells. Cancer Res. 1987; 47: 1234
   Google Scholar
• Sheen Y. Y., Katzenellenbogen B. S. Antiestrogen stimulation of the production of a 37,000 molecular weight secreted protein and estrogen stimulation of the production of a 32,000 molecular weight secreted protein in MCF-7 human breast cancer cells. Endocrinology 1987; 120: 1140
   PubMedGoogle Scholar
• Gase J.-M., Renoir J.-M., Radanyi C., Joab I., Tuohimaa P., Baulieu E. E. Progesterone receptor in the chick oviduct: an immunohistochemical study with antibodies to distinct receptor components. J. Cell Biol. 1984; 99: 1193
   Google Scholar
• Welshons W. V., Krummel B. M., Gorski J. Nuclear localization of unoccupied receptors for glucocorticoids, estrogen and progesterone in GH3, cells. Endocrinology 1985; 117: 2140
   PubMed Web of Science ®Google Scholar
• Westley B., Rochefort H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 1980; 20: 353
   PubMed Web of Science ®Google Scholar
• Veith F. O., Capony F., Garcia M., Chatelard J., Pujol H., Veith F. Z., Rochefort H. Release of estrogen-induced glycoprotein with a molecular weight of 52,000 by breast cancer cells in primary culture. Cancer Res. 1983; 43: 1861
   Google Scholar
• Edwards D. P., Adam D. J., Mc Guire W. L. Estradiol stimulates synthesis of a major intracellular protein in human breast cancer cell line MCF-7. Breast Cancer Res. Treat. 1981; 1: 209
   Google Scholar
• Westley B., May F. E. B., Brown M. C., Krust A., Chambon P., Lippman M. E., Rochefort H. Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52- and 160-kilodalton proteins in MCF-7 cells and two tamoxifen-resistant sublines. J. Biol. Chem. 1984; 259: 10030
   PubMed Web of Science ®Google Scholar
• Davidson N. E., Bronzert D. A., Chambon P., Gelman E. P., Lippman M. E. Use of two MCF-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products. Cancer Res. 1986; 46: 1904
   Google Scholar
• Teixidó J., Gilmore R., Lee D. C., Massagué J. Integral membrane glycoprotein properties of the prohormone pro-transforming growth factor α. Nature (London) 1987; 326: 883
   PubMedGoogle Scholar
• Osborne C. K., Hamilton B., Titus G., Livingston R. B. Epidermal growth factor stimulation of human breast cancer cells in culture. Cancer Res. 1980; 40: 2361
   PubMed Web of Science ®Google Scholar
• Osborne C. K., Hamilton B., Nover M. Receptor binding and processing of epidermal growth factor by human breast cancer cells. J. Clin. Endocrinol. Metab. 1982; 55: 86
   PubMed Web of Science ®Google Scholar
• Fitzpatrick S. L., La Chance M. P., Schultz G. S. Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture. Cancer Res. 1984; 44: 3442
   PubMed Web of Science ®Google Scholar
• Jordan V. C., Robinson S. P., Welshons W. V. Resistance to antiestrogen therapy. Resistance to Antineoplastic Agents., D. Kessel. CRC Press, Boca Raton, Fla., in press
   Google Scholar
• Le Clercq G. Technical pitfalls, methodological improvements and quality control of steroid hormone receptor assays. Eur. J. Cancer Clin. Oncol. 1987; 23: 453
   Google Scholar
• Duffy M. J. Assay of estradiol receptor in human breast carcinoma using the gamma emitting ligand, 16α[125I]iodoestradiol. J. Steroid Biochem. 1982; 16: 343
   Google Scholar
• Progesterone Receptors in Normal and Neoplastic Tissue, W. L. Mc Guire, J. P. Raynaud, E. E. Baulieu. Raven Press, New York 1977
   Google Scholar
• Le Clercq G. Routing assays for steroid hormone receptors. Recent Results in Cancer Research, G. LeClercq, S. Toma, R. Paridaens, J. C. Heuson. Springer-Verlag, Heidelberg 1984; 901: 12
   Google Scholar
• Seematter R. H., Hoffman P. G., Kuhn R. W., Siiteri P. K., Lockwood L. C. Comparison of [3H]progesterone and [6,73H]-17, 21-dimethyl-19-nor-pregna 4,9-diene-3-,20-dione for the measurement of progesterone receptors in human malignant tissue. Cancer Res. 1978; 38: 2800
   Google Scholar
• Duffy M. J. Measurement of progesterone receptor in human breast tumor using the synthetic progestin 16α-ethy1–21-hydroxy-l9-nor-4-pregna 4-ene-3,20-dione. J. Steroid Biochem. 1980; 13: 1005
   Google Scholar
• Muensch H., Maslow W. C. Interference of O.C.T.r` embedding compound with hormone receptor assay. Am. J. Clin. Pathol. 1984; 82: 89
   Google Scholar
• Mc Guire W. L., Garza De La M. Improved sensitivity in the measurement of estrogen receptors in human breast cancer. J. Clin. Endocrinol. Metab. 1973; 37: 986
   Google Scholar
• Ratajczak T., Hahnel R. The protection, stabilization and reactivation of estradiol receptors in human myometrial cytosol. Biochim. Biophys. Acta 1974; 338: 104
   Google Scholar
• Anderson K. M., Phelon J., Marogil M., Hendrickson C., Economou S. Sodium molybdate increases the amount of progesterone and estrogen receptor detected in certain breast cancer cytosols. Steroids 1980; 35: 273
   Google Scholar
• Niu E.-M., Neal R. M., Pierce V. Structural similarity of molybdate stabilized steroid receptors in human breast tumors, uteri and leukocytes. J. Steroid Biochem. 1981; 15: 1
   Google Scholar
• Pichon M. F., Milgrom E. Characterization and assay of progesterone receptors in human mammary carcinoma. Cancer Res. 1977; 37: 464
   Google Scholar
• Martin K. G., Ames B. N. A method for determining the sedimentation behaviour of enzymes. Application to protein mixtures. J. Biol. Chem. 1961; 236: 1372
   PubMed Web of Science ®Google Scholar
• Wittliff J. L., Hilf R., Brooks W. F., Savlov E. D., Hall T. C., Orlando R. A. Specific estrogen-binding capacity of the cytoplasmic receptor in normal and neoplastic breast tissues of humans. Cancer Res. 1971; 32: 1983
   Google Scholar
• Jensen E. V., Block G. E., Smith S., Kyser K., De Sombre E. R. Estrogen receptors and breast cancer response to adrenalectomy. Natl. Cancer Inst. Monogr. 1971; 34: 55
   PubMedGoogle Scholar
• Mc Guire W. L., Garza De La M. Similarity of the estrogen receptors in human and rat mammary carcinoma. J. Clin. Endocrinol. Metab. 1973; 36: 548
   Google Scholar
• Mc Guire W. L. Estrogen receptors in human breast cancer. J. Clin. Invest. 1973; 52: 73
   Google Scholar
• Spaeren U., Olsen S., Brennhovd I., Efskind J., Pihl A. Content of estrogen receptors in human breast cancer. Eur. J. Cancer 1973; 9: 353
   Google Scholar
• Wittliff J. L. Specific receptors of the steroid hormones in breast cancer. Semin. Oncol. 1974; 1: 109
   PubMedGoogle Scholar
• Jordan V. C., Prestwich G. Binding of [3H]tamoxifen in rat uterine cytosols: a comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis. Mol. Cell. Endocrinol. 1977; 8: 179
   PubMed Web of Science ®Google Scholar
• Holmen L. F., Moline C., McGrath G., Barron E. J. Use of the vertical rotor to facilitate estrogen and progesterone receptor analysis. Clin. Chem. 1978; 24: 1609
   Google Scholar
• Korenman S. G. Radio-ligand binding assay of specific estrogens using a soluble uterine macromolecule. J. Clin. Endocrinol. Metab. 1968; 28: 127
   PubMed Web of Science ®Google Scholar
• Korenman S. G., Dukes B. A. Specific estrogen binding by the cytoplasm of human breast carcinoma. J. Clin. Endocrinol. Metab. 1970; 30: 639
   PubMed Web of Science ®Google Scholar
• Hahnel R., Twaddle E. Estrogen receptors in human breast cancer. I. Methodology and characterization of receptors. Steroids 1971; 18: 653
   Google Scholar
• Feherty P., Farrer-Brown G., Kellie A. E. Oestradiol receptors in carcinoma and benign disease of the breast: an in vitro assay. Br. J. Cancer 1971; 25: 697
   PubMed Web of Science ®Google Scholar
• Hahnel R., Twaddle E. Estimation of the association constant of the estrogen receptor complex in human breast cancer. Cancer Res. 1973; 33: 559
   PubMedGoogle Scholar
• E.O.R.T.C. Breast Cancer Co-operative Group, Standards for the assessment of estrogen receptors in human breast cancer. Eur. J. Cancer 1973; 9: 379
   Web of Science ®Google Scholar
• Le Clercq G., Heuson J. C., Schoenfeld R., Mattheiem W. H., Tagnon H. J. Estrogen receptors in human breast cancer. Eur. J. Cancer. 1973; 9: 665
   Google Scholar
• Le Clercq C., Heuson J. C., Deboel M. C., Mattheiem W. H. Oestrogen receptors in breast cancer: a changing concept. Br. Med. J. 1975; 1: 185
   Google Scholar
• Scatchard G. The attraction of proteins for small molecules and ions. Ann. N. Y. Acad. Sci. 1949; 51: 660
   Web of Science ®Google Scholar
• Chamness G. C., Mc Guire W. L. Scatchard plots: common errors in correction and interpretation. Steroids 1975; 26: 538
   PubMed Web of Science ®Google Scholar
• Haldane J. B. Graphical methods in enzyme chemistry. Nature (London) 1957; 179: 832
   Google Scholar
• Braunsberg H. Mathematical analysis of data from receptor assays. Recent Results in Cancer Research, G. LeClercq, S. Toma, R. Paridaens, J. C. Heuson. Springer-Verlag, Heidelberg 1984; 91: 18
   Google Scholar
• Keightley D. D., Gessiz N. A. The Woolf plot is more reliable than the Scatchard plot in analyzing data from hormone receptor assays. J. Steroid Biochem. 1980; 13: 1317
   PubMedGoogle Scholar
• Miller L. K., Tuazon F. B., Niu E., Sherman M. R. Human breast tumor estrogen receptor: effects of molybdate and electrophoretic analysis. Endocrinology 1981; 108: 1369
   Google Scholar
• Borjesson B. W., Tesoriero C. J. Effect of molybdate on classification of estrogen and progesterone receptor status in human breast cancer. J. Steroid Biochem. 1985; 13: 949
   Google Scholar
• Raam S., Teixeira T. Effect of sodium molybdate on protein measurements: quality control aspects of steroid hormone receptor assay. Eur. J. Cancer Clin. Oncol. 1985; 21: 1219
   Google Scholar
• Poulsen H. S. Oestrogen receptor assay—limitation of the method. Eur. J. Cancer Clin. Oncol. 1981; 17: 495
   Google Scholar
• Powell B. L., Garza De La M., Clark G. M., Mc Guire W. L. Estrogen receptor measurement in low-protein breast cancer cytosols. Breast Cancer Res. Treat. 1981; 1: 33
   Google Scholar
• Petterson K. S. I., Vanharanta R. M., Soderholm J. R. M. Pitfalls in the dextran-coated charcoal assay of estrogen receptors in breast cancer tissue. J. Steroid Biochem. 1985; 22: 39
   Google Scholar
• Powell B., Garola R. E., Chamness G. C., Mc Guire W. L. Measurement of progesterone receptors in human breast cancer biopsies. Cancer Res. 1979; 39: 1678
   Google Scholar
• Namkung P. C., Petra P. H. Measurement of progesterone receptors in human breast tumors: comparison of various methods of analysis. J. Steroid Biochem. 1981; 14: 851
   Google Scholar
• Tandon A. K., Chamness G. C., Mc Guire W. L. Estrogen receptor in very small breast tumor specimens: a modified charcoal-gelatin assay. Cancer Res. 1986; 46: 3375
   Google Scholar
• Greene G. L., Closs L. E., Fleming H., De Sombre E. R., Jensen E. V. Antibodies to estrogen receptor: immunochemical similarity of estrophilin from various mammalian species. Proc. Natl. Acad. Sci. USA 1977; 74: 3681
   Google Scholar
• Greene G. L., Closs L. E., De Sombre E. R., Jensen E. V. Antibodies to estrophilin: comparison between rabbit and goat antisera. J. Steroid Biochem. 1979; 11: 133
   Google Scholar
• Raam S., Peters L., Rafkind I., Putnam E., Longcope C., Cohen J. L. Simple methods for production and characterization of rabbit antibodies to human breast tumor estrogen receptors. Mol. Immunol. 1981; 18: 143
   Google Scholar
• Raam S., Nemeth E., Tamura H., O'Brian D. S., Cohen J. L. Immunohistochemical localization of estrogen receptors in human mammary carcinoma using antibodies to the receptor protein. Eur. J. Cancer Clin. Oncol. 1982; 18: 1
   PubMedGoogle Scholar
• Tate A. C., Greene G. L., De Sombre E. R., Jensen E. V., Jordan V. C. Differences between estrogen and antiestrogen receptor complexes from human breast tumors identified with an antibody against the estrogen receptor. Cancer Res. 1984; 44: 1012
   Google Scholar
• Tate A. C., De Sombre E. R., Greene G. L., Jensen E. V., Jordan V. C. Interaction of [3H]estradiol- and [3H]monohydroxytamoxifen-estrogen receptor complexes with a monoclonal antibody. Breast Cancer Res. Treat. 1983; 3: 267
   Google Scholar
• Le Clercq G., Bojar H., Goussard J. Abbott monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer: a European multicenter study. Cancer Res. 1986; 46: 4233s
   Google Scholar
• Di Fronzo G., Miodini P., Brivio M. Comparison of immunocytochemical and radioligand binding assays for estrogen receptors in human breast tumors. Cancer Res. 1986; 46: 4278s
   Web of Science ®Google Scholar
• Goussard J., Lechevrel C., Martin P. M. Comparison of monoclonal antibodies and tritiated ligands for estrogen receptor assays in 241 breast cancer cytosols. Cancer Res. 1986; 46: 4282s
   PubMed Web of Science ®Google Scholar
• Heubner A., Beck T., Grill H.-J. Comparison of immunocytochemical estrogen receptor assay, estrogen receptor immunoassay and radioligand-labeled estrogen receptor assay in human breast cancer and uterine tissue. Cancer Res. 1986; 46: 4291s
   Google Scholar
• Nicholson R. I., Colin P., Francis A. B. Evaluation of an enzyme immunoassay for estrogen receptors in human breast cancers. Cancer Res. 1986; 46: 4299s
   PubMed Web of Science ®Google Scholar
• Jordan V. C., Jacobson H. I., Keenan E. J. Determination of estrogen receptor in breast cancer using monoclonal antibody technology: results of a multicenter study in the United States. Cancer Res. 1986; 46: 4237s
   Web of Science ®Google Scholar
• Mirecki D. M., Jordan V. C. Steroid hormone receptors and human breast cancer. Lab. Med. 1985; 16: 287
   Google Scholar
• Bojar H. Quality control requirements in estrogen receptor determination. Cancer Res. 1986; 46: 4249
   Web of Science ®Google Scholar
• King W. J., De Sombre E. R., Jensen E. V., Greene G. L. Comparison of immunocytochemical and steroid-binding assays for estrogen receptors in human breast tumors. Cancer Res. 1985; 45: 293
   PubMed Web of Science ®Google Scholar
• Pertschuk L. P., Eisenberg K. B., Carter A. C., Feldman J. G. Immunohistological localization of estrogen receptors in breast cancer with monoclonal antibodies. Cancer 1985; 55: 1513
   PubMed Web of Science ®Google Scholar
• Mc Carty K. S., Jr., Miller L. S., Cox E. B., Konrath J., Mc Carthy K. S., Sr. Estrogen receptor analyses correlation of biochemical and immunochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lb. Med. 1985; 109: 716
   Google Scholar
• Hawkins R. A., Songster K., Krajewski A. Histochemical detection of estrogen receptors in breast carcinoma: a successful technique. Br. J. Cancer 1986; 53: 407
   PubMed Web of Science ®Google Scholar
• De Sombre E. R., Thorpe S. M., Rose C., Blough R. W., Anderson K. W., Rasmussen B. B., King W. J. Prognostic usefulness of estrogen receptor immunocytochemical assays (ER-ICA) for human breast cancer. Cancer Res. 1986; 46: 4256s
   Web of Science ®Google Scholar
• Pousen H. S., Ozzello L., King W. L., Greene G. L. The use of monoclonal antibodies to estrogen receptors (ER) for immunoperoxidase detection of ER in paraffin sections of human breast cancer tissues. J. Histochem. Cytochem. 1985; 33: 87
   Google Scholar
• Marchetti E., Querzoli P., Moncharmont B., Parikh I., Bagni A., Marzola A., Fabris G., Nenci I. Immunocytochemical demonstration of estrogen receptors by monoclonal antibodies in human breast cancer: correlation with estrogen receptor assay by dextran-coated charcoal method. Cancer Res. 1987; 47: 2508
   PubMed Web of Science ®Google Scholar
• Chamness G. C., Mercer D. W., Mc Guire W. L. Are histochemical methods for estrogen receptors valid?. J. Histochem. Cytochem. 1980; 28: 792
   PubMed Web of Science ®Google Scholar
• Danguy A., Le Clercq G., Pattyn G., De Vleeschruwel N., Pasteels J. L., Heuson J. C. Cytochemical analysis of human breast cancers with sex steroid conjugates. Comparison with biochemical oestrogen receptor. Anticancer Res. 1981; 1: 361
   Google Scholar
• Berns E. M. J. J., Mulder E., Rommerts F. F. G., Blankenstein M. A., de Graaf E., Van der Molen H. J. Fluorescent ligands used in histochemistry do not discriminate between estrogen receptorpositive and receptor-negative human tumor cell lines. Breast Cancer Res. Treat. 1984; 4: 195
   Google Scholar
• Mc Guire W. L., Carbone P. P., Vollmer E. P. Estrogen Receptors in Human Breast Cancer. Raven Press, New York 1975
   Google Scholar
• De Sombre E. R., Greene G. L., Jensen E. V. Estrophilin and endocrine responsiveness of breast cancer in hormones, receptors and breast cancer. Progress in Cancer Research and Therapy, W. L. Mc Guire. Raven Press, New York 1978; 10: 1
   Google Scholar
• Saez S., Martin P. M., Chouvet C. D. Estradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels. Cancer Res. 1978; 38: 3468
   PubMed Web of Science ®Google Scholar
• Heise E., Garlich M. Estradiol receptor in human breast cancers throughout the menstrual cycle. Oncology 1982; 39: 340
   PubMed Web of Science ®Google Scholar
• Fishman J., Nisselbaum J. S., Menendez-Botet C. J. Estrone and estradiol content in human breast tumors: relationship to estradiol receptors. J. Steroid Biochem. 1977; 8: 893
   PubMedGoogle Scholar
• Elwood J. M., Godolphin W. Oestrogen receptors in breast tumors: associations with age, menopausal status and epidemiological and clinical features in 735 patients. Br. J. Cancer 1980; 42: 635
   PubMed Web of Science ®Google Scholar
• Mc Carty K. S., Jr., Silva J. S., Cox E. B. Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast. Ann. Surg. 1983; 197: 123
   Google Scholar
• Clark G. M., Osborne C. K., Mc Guire W. L. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J. Clin. Oncol. 1984; 2: 1102
   PubMed Web of Science ®Google Scholar
• Mc Carty K. S., Jr., Barton T. K., Fetter B. F., Woodard B. H., Mossler J. A., Reeves W., Daly J., Wilkinson W. E., Mc Carty K. S., Sr. Correlation of estrogen and progesterone receptors with histological differentiation of mammary carcinoma. Cancer 1980; 46: 2851
   Google Scholar
• King R. J. B. Analysis of estradiol and progesterone receptors in early and advanced breast tumors. Cancer 1980; 46: 2818
   PubMedGoogle Scholar
• Hawkins R. A., Roberts M. M., Forrest A. P. N. Oestrogen receptors and breast cancer: current status. Br. J. Surg. 1980; 67: 153
   PubMedGoogle Scholar
• Fisher E. R., Sass R., Fisher B. Pathological findings from the National Surgical Adjuvant Breast Project. Cancer 1987; 59: 1554
   Google Scholar
• Hull D. F., Clark G. M., Osborne C. K., Chamness G. C., Knight W. A., Mc Guire W. L. Multiple estrogen receptor assays in human breast cancer. Cancer Res. 1983; 43: 413
   PubMed Web of Science ®Google Scholar
• Gross G. E., Clark G. M., Chamness G. C., Mc Guire W. L. Multiple progesterone receptor assays in human breast cancer. Cancer Res. 1984; 44: 836
   PubMed Web of Science ®Google Scholar
• Kiang D. T., Kennedy B. J. Factors affecting estrogen receptors in breast cancer. Cancer 1977; 40: 1571
   Google Scholar
• Rosen P. P., Menendez-Botet C. J., Urban J. A., Fracchia A., Schwartz M. K. Estrogen receptor protein in multiple tumor specimens from individual patients with breast cancer. Cancer 1977; 39: 2194
   PubMed Web of Science ®Google Scholar
• Le Clercq G., Heuson J., Deboel M., Matteiem W. H. Oestrogen receptors in breast cancer: a changing concept. Br. Med. J. 1975; 1: 185
   Google Scholar
• Sighakowinta A., Potter H. G., Burok J. R. Estrogen receptors and natural course of breast cancer. Ann. Surg. 1976; 183: 84
   Google Scholar
• Brennan M. J., Donegan W. L., Appleby D. E. The variability of estrogen receptors in metastatic breast cancer. Am. J. Surg. 1979; 137: 260
   PubMedGoogle Scholar
• Klinga K., Kaufman M., Runnebsum B., Kubli F. Distribution of estrogen and progesterone receptors on primary tumor and lymph nodes in individual patients with breast cancer. Oncology 1982; 39: 337
   PubMedGoogle Scholar
• De Sombre E. R., Jensen E. V. Estrophilin assays in breast cancer: quantitative features and application to the mastectomy specimen. Cancer 1980; 46: 2783
   Google Scholar
• Perez R., Pascual M., Macias A., Lage A. Epidermal growth factor receptors in human breast cancer. Breast Cancer Res. Treat. 1984; 4: 189
   PubMed Web of Science ®Google Scholar
• Fitzpatrick S. L., Brightwell J., Wittliff J. L., Barrows G. H., Schultz G. S. Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels. Cancer Res. 1984; 44: 3448
   PubMed Web of Science ®Google Scholar
• Sainsbury J. R. C., Farndon J. R., Sherbet G. V., Harris A. L. Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet 1985; 1: 364
   PubMed Web of Science ®Google Scholar
• Skoog L., Macias A., Azaredo E., Lambardero J., Klintenberg C. Receptors for EGF and oestradiol and thymidine kinase activity in different histological subgroups of human mammary carcinomas. Br. J. Cancer 1986; 54: 271
   PubMed Web of Science ®Google Scholar
• Koenders A., Benraad T. J. Quality control of steroid receptor assays in the Netherlands. Recent Results in Cancer Research, G. Le Clercq, S. Toma, R. Paridaens, J. C. Heuson. Springer-Verlag, Heidelberg 1984; 91: 110
   Google Scholar
• Zava D. T. Interlaboratory variability in the determination of estrogen and progesterone receptor content in human breast tumors: quality control in Switzerland. Recent Results in Cancer Research, G. Le Clercq, S. Toma, R. Paridaens, J. C. Heuson. Springer-Verlag, Heidelberg 1984; 91: 122
   Google Scholar
• Wittliff J. L., Durant J. R., Fisher B. Methods of steroid receptor analyses and their quality control in the clinical laboratory. Physiopathology of Endocrine Disease and Mechanisms of Hormone Action, R. J. Soto, et al. Alan R. Liss, New York 1981; 397
   Google Scholar
• Jordan V. C., Zava D. T., Eppenburger U., Kiser A., Sebek S., Dowdle E., Krozowski Z., Bennett R. C., Funder J., Holdaway I. M., Wittliff J. L. Reliability of steroid hormone receptor assays: an international study. Eur. J. Cancer Clin. Oncol. 1983; 19: 357
   PubMedGoogle Scholar
• Raam S., Gelman R., Cohen J. Estrogen receptor assays: interlaboratory and intralaboratory variation in the measurement of receptors using dextran-coated charcoal technique: a study sponsored by ECOG. Eur. J. Cancer Clin. Oncol. 1981; 17: 643
   Google Scholar
• Oxley D. K., Haven G. T., Wittliff J. L., Gilbo D. Precision in estrogen and progesterone receptor assays. Am. J. Clin. Pathol. 1982; 78: 587
   PubMed Web of Science ®Google Scholar
• Konders A., Thorpe S. M. Standardization of steroid receptor assays in human breast cancer. I. Reproducibility of estradiol and progesterone receptor assays. Eur. J. Cancer Clin. Oncol. 1983; 19: 1221
   Google Scholar
• King R. J. B. Quality control of estradiol receptor analysis: the United Kingdom experience. Cancer 1980; 46: 2822
   PubMed Web of Science ®Google Scholar
• Cowan S., Leake R. E. British interlaboratory quality assessment of steroid receptor assays. Recent Results in Cancer Research, G. Le Clercq, S. Toma, R. Paridaens, J. C. Heuson. Springer-Verlag, Heidelberg 1984; 91: 98
   Google Scholar
• Koenders A., Geurts-Moespot J., Hendriks T., Benraad T. The Netherlands interlaboratory quality control program of steroid receptor assays in breast cancer. Estrogen Receptor Assays in Breast Cancer. Laboratory Discrepancies and Quality Assurance, G. A. Safarty, A. R. Nash, D. D. Keighthly. Masson, SydneyAustralia 1981; 69
   Google Scholar
• Koenders A., Thorpe S. M. Standardization of steroid receptor assays in human breast cancer. II. Samples with low receptor content. Eur. J. Cancer Clin. Oncol. 1983; 19: 1467
   PubMedGoogle Scholar
• Nishigori H., Toft D. Inhibition of progesterone receptor activation by sodium molybdate. Biochemistry 1980; 19: 77
   PubMedGoogle Scholar
• Walt A. J., Singhakaowinta A., Brooks S. C., Cortes A. The surgical implications of estrophile protein estimations in carcinoma of the breast. Surgery 1976; 80: 506
   Google Scholar
• Knight W. A., III, Livingston R. B., Gregory E. J., Mc Guire W. L. Estrogen receptor as an independent prognostic factor for early recurrence. Cancer Res. 1977; 37: 4669
   PubMed Web of Science ®Google Scholar
• Rich M. A., Furmanski P., Brooks S. C. Prognostic value of estrogen receptor determinations in patients with breast cancer. Cancer Res. 1978; 38: 4296
   Google Scholar
• Maynard P. V., Blamey R. W., Elston C. W., Haybittle J. L., Griffiths K. Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res. 1978; 38: 4292
   Google Scholar
• Cooke T., George D., Shields R., Maynard P. V., Griffiths K. Oestrogen receptors and prognosis in early breast cancer. Lancet 1979; 1: 995
   Google Scholar
• Allegra J. C., Lippman M. E., Simon R., Thompson E. B., Barlock A., Green L., Huff K. K., Do H. M. T., Aitken S. C., Warren R. Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat. Rep. 1979; 63: 1271
   PubMedGoogle Scholar
• Raemaekers J. M. M., Beex L. V. A. M., Koenders A. J. M., Pieters G. F. F. M., Smals A. G. H., Benraad T. J., Kloppenborg P. W. C. Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow up. Breast Cancer Res. Treat. 1985; 6: 123
   PubMed Web of Science ®Google Scholar
• Osborne C. K., Yochmowitz M. G., Knight W. A., III, Mc Guire W. L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46: 2884
   PubMed Web of Science ®Google Scholar
• Pichon M. F., Pallud C., Brunet M., Milgrom E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res. 1980; 40: 3357
   PubMed Web of Science ®Google Scholar
• Westerberg H., Gustafson S. A., Nordenskjöld B., Stilfesward C., Wallgren A. Estrogen receptor levels and others factors in early recurrence of breast cancer. Int. J. Cancer 1980; 26: 429
   PubMed Web of Science ®Google Scholar
• Hawkins R. A., Roberts M. M., Forrest A. P. M. Oestrogen receptors and breast cancer: current status. Br. J. Surg. 1980; 67: 153
   PubMedGoogle Scholar
• Cheix F., Biron A., Bailly C., Mayer M., Pommatau E., Saez S. Cancer du sein operable: valeur pronostique du nombre des recepteurs d'estradiol. Nouv. Presse Med. 1980; 9: 933
   Google Scholar
• Blamey R. W., Bishop H. M., Blake J. R. S., Doyle P. J., Elston C. W., Haybittle J. L., Nicholson R. I., Griffiths K. Relationship between primary breast cancer tumor receptor status and patient survival. Cancer 1980; 46: 2765
   Google Scholar
• Rainer H., Bettelheim P., Bieglmayer C. L., Chaput B., Jakesz R., Kees A., Kolb R., Mörz R., Moser K., Reiner G., Schemper M., Spona J. Prognostische Bedeutung von östrogenrezeptoren beim Mammakarzinom. Wien. Klin. Wochenschr. 1980; 92: 796
   Google Scholar
• Gapinsky P. V., Donegan W. L. Estrogen receptors and breast cancer: prognostic and therapeutic implications. Surgery 1980; 88: 386
   Google Scholar
• Hartveit F., Maartmann-Moe H., Stoa K. F., Tangen M., Thorsen T. Early recurrence in estrogen receptor negative breast carcinomas. Acta Chir. Scand. 1980; 146: 93
   Google Scholar
• Valagusa P., Di Fronzo G., Bignami P., Buzzoni R., Bonnadona G., Veronesi U. Prognostic importance of estrogen receptors to select node negative patients for adjuvant chemotherapy. Adjuvant Therapy of Cancer III, S. E. Salmon, S. E. Jones. Grune & Stratton, New York 1981; 329
   Google Scholar
• Bertuzzi A., Vezzoni P., Ronchi E. Prognostic importance of progesterone receptors (PR) alone or in combination with estrogen receptors (ER) in node negative (N-) breast carcinoma. Proc. Am. Soc. Clin. Oncol. 1981; 447, Abstr.
   Google Scholar
• Samaan N. A., Buzdar A. K., Aldinger K. A., Schultz P. N., Yang K. P., Romsdahl M. M., Martin R. Estrogen receptor: a prognostic factor in breast cancer. Cancer 1981; 47: 554
   PubMed Web of Science ®Google Scholar
• Kinne D. W., Ashikari R., Butler A., Menendez-Botet C., Rosen P. P., Schwartz M. Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer 1981; 47: 2364
   PubMedGoogle Scholar
• Godolphin W., Elwood J. M., Spinelli J. J. Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer: a study of 583 patients. Int. J. Cancer 1981; 28: 677
   PubMed Web of Science ®Google Scholar
• Crowe J. P., Hubay C. A., Pearson O. H., Marshall J. S., Rosenblatt J., Mansour E. G., Hermann R. E., Jones J. C., Flynn W. J., Mc Guire W. L., et al. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res. Treat. 1982; 2: 171
   PubMedGoogle Scholar
• Raemaekers J. M. M., Beex L. V. A. M., Koenders A. J. M., Smals A. G. H., Pieters G. F. F. M., Benraad Th. J., Kloppenborg P. W. C. And the Mammacarcinoom Werkgroep De prognostiche betekenis van onderzoek naar receptaractiviteit voor estradiol in the tumorweefsel van patienten met een primair mammacarcinoom. Ned. Tijdschr. Geneeskd. 1982; 126: 1493
   Google Scholar
• Neifeld J. P., Lawrence W., Jr., Brown P. W., Banks W. L., Ierz J. J. Estrogen receptors in primary breast cancer. Arch. Surg. 1982; 117: 753
   Google Scholar
• Paterson A. H. G., Zuck V. P., Szafron O., Lees A. W., Hanson J. Influence and significance of certain prognostic factors on survival in breast cancer. Eur. J. Cancer Clin. Oncol. 1982; 18: 937
   Google Scholar
• Logan L. A., Cripps M. C., Hirte W. E., Rapp E. F. The estrogen receptor test: a prognostic tool in primary breast cancer. Can. J. Surg. 1982; 25: 581
   Google Scholar
• Paswal M. R., Macias A., Moreno L., Lage A. Factors associated with prognosis in human breast cancer. III. Estradiol receptors and short-term relapse. Neoplasia 1983; 30: 589
   Google Scholar
• Clark G. M., Mc Guire W. L., Hubay C. A., Pearson O. H., Marshall J. S. Progesterone receptors as a prognostic factor in stage II breast cancer. N. Engl. J. Med. 1983; 309: 1343
   PubMed Web of Science ®Google Scholar
• Hilf R., Feldstein M. L., Gibson S. L., Savlov E. D. The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 1980; 45: 1993
   Google Scholar
• Bloom N. D., Degenshein G. A. Estrogen receptors and disease-free interval: a dissenting opinion. Breast 1980; 6: 25
   Google Scholar
• Skinner J. R., Wanebo H. J., Betsill W. L., Wilhelm M. C., Drake Ch. R., Mc Lead R. M. Evaluation of the pathologic and prognostic correlates of estrogen receptors in primary breast cancer. Ann. Surg. 1982; 196: 636
   Google Scholar
• Kaufmann M., Klinga K. Mògliche prognostische Kriterien zur Therapie-Verbesserung beim primären Mamakarzinom. Geburtschilfe Frauenheilk 1982; 42: 501
   Google Scholar
• Stewart J. F., King R. J. B., Winter P. J., Tong D., Hayward J. L., Rubens R. D. Oestrogen receptors, clinical features and prognosis in stage III breast cancer. Eur. J. Cancer Clin. Oncol. 1982; 18: 1315
   Google Scholar
• Stewart J. F., Rubens R. D., Millis R. R., King R. J. B., Hayward J. L. Steroid receptors and prognosis in operable (stage I and II) breast cancer. Eur. J. Cancer Clin. Oncol. 1983; 19: 1381
   PubMedGoogle Scholar
• Ciatto S., Bravetti P., Cardona G., Cataliotti L., Crescioli R., Herd-Smith A., Messeri G. Prognostic role of estrogen receptor determinations in breast cancer. Tumori 1983; 69: 527
   Google Scholar
• Mason B. H., Holdaway I. M., Hullins P. R., Yee L. H., Kay R. G. Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res. 1983; 43: 2985
   PubMed Web of Science ®Google Scholar
• Caldarola L., Calderini P., Volterrani P., Di Carlo P., Gaglia P. The correlation between estrogen receptor status, axillary-node metastases and disease-free interval after surgery in primary breast cancer. Ital. J. Surg. Sci. 1983; 13: 179
   Google Scholar
• Howell A., Harland R. N. C., Bramwell V. H. C., Swindell R., Barnes D. M., Redford J., Wilkinson M. J. S., Crowther D., Sellwood R. A. Steroid receptors and survival after first relapse in breast cancer. Lancet 1984; 1: 588
   Google Scholar
• Alanko A., Heinonen E., Schein T. M., Tolppanen E. M., Vihko R. V. Oestrogen and progestrone receptors and disease-free interval in primary breast cancer. Cancer 1984; 50: 667
   Google Scholar
• Aamdal S., Børmer O., Jørgensen O., Høst H., Eliassen G., Kaalhus O., Pihl A. Estrogen receptors and long-term prognosis in breast cancer. Cancer 1984; 53: 2525
   PubMed Web of Science ®Google Scholar
• Parl F. F., Schmidt B. P., Dupont W. D., Wagner R. K. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastases and histological grading. Cancer 1984; 54: 2237
   PubMed Web of Science ®Google Scholar
• Häahnel R., Woodings T., Vivian A. B. Prognostic value of estrogen receptors in primary breast cancer. Cancer 1979; 44: 671
   Google Scholar
• Furmanski P., Saunders D. E., Brook S. C., Rich M. A. and the Breast Cancer Prognostic Study Clinical and Pathological Associates, The prognostic value of estrogen receptor determinations in patients with primary breast cancer: an update. Cancer 1980; 46: 2794
   PubMed Web of Science ®Google Scholar
• van Maillot K., Harke W., Prestele H. Prognostic significance of the steroid receptor content in primary breast cancer. Arch. Gynaekol. 1982; 231: 1985
   Google Scholar
• Howat J. M. T., Barnes D. M., Harris A., Swindell R. The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. Br. J. Cancer 1983; 47: 621
   Google Scholar
• Saez S., Cheiz F., Asselain B. Prognostic value of estrogen and progesterone receptors in primary breast cancer. Breast Cancer Res. Treat. 1983; 3: 345
   PubMed Web of Science ®Google Scholar
• Butler J. A., Bretsky S., Menendez-Botet C., Kinne D. W. Estrogen receptor protein of breast cancer as a predictor of recurrence. Cancer 1985; 55: 1178
   PubMed Web of Science ®Google Scholar
• Williams M. R., Todd J. H., Ellis I. O., Dowle C. S., Haybittle J. L., Elston C. W., Nicholson R. I., Griffiths K., Blamey R. W. Oestrogen receptors in primary and advanced breast cancer. An eight-year review of 704 cases. Br. j. Cancer 1987; 55: 67
   PubMedGoogle Scholar
• Maynard P. V., Davis C. J., Blamey R. W., Elston C. W., Johnson J., Griffiths K. Relationship between oestrogen-receptor content and histological grade in human primary breast tumors. Br. J. Cancer 1918; 38: 745
   Google Scholar
• Robinson S. P., Jordan V. C. The metabolism of steroid-modifying anticancer agents. Pharm. Ther. 1988; 36: 41
   Google Scholar
• Furr B. J. A., Jordan V. C. The pharmacology and clinical uses of tamoxifen. Pharm. Ther. 1984; 25: 127
   PubMed Web of Science ®Google Scholar
• Skidmore J. R., Walpole A. L., Woodburn J. Effect of some triphenylethylenes on oestradiol binding in vitro to macromolecues from uterus and anterior pituitary. J. Endocrinol. 1972; 52: 289
   PubMed Web of Science ®Google Scholar
• Jordan V. C., Koerner S. Tamoxifen (ICI46, 474) and the human carcinoma 8S oestrogen receptor. Eur. J. Cancer 1975; 11: 205
   PubMed Web of Science ®Google Scholar
• Jordan V. C., Collins M. M., Rowsby L., Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 1977; 75: 305
   PubMed Web of Science ®Google Scholar
• Jordan V. C., Bain R. R., Brown R. R., Gosden B., Santos M. A. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res. 1983; 43: 1446
   Google Scholar
• Soule H. D., Mc Grath C. M. Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice. Cancer Lett. 1980; 10: 177
   PubMed Web of Science ®Google Scholar
• Shafie S. M., Grantham F. H. Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic mice. J. Natl. Cancer Inst. 1981; 67: 51
   PubMed Web of Science ®Google Scholar
• Jordan V. C., Fritz N. F., Gottardis M. M. Strategies for breast cancer therapy. J. Steroid Biochem. 1987; 27: 493
   Google Scholar
• Osborne C. K., Hobbs K., Clark G. M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985; 45: 584
   PubMed Web of Science ®Google Scholar
• Gottardis M. M., Robinson S. P., Jordan V. C. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J. Steroid Biochem., in press
   Google Scholar
• Cummings F. J., Gray R., Davis T. E., Tormey D. C., Harris J. E., Falkson G., Arsenau J. Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. Ann. Intern. Med. 1985; 103: 324
   PubMed Web of Science ®Google Scholar
• Baum M. and Members of the Nolvadex Adjuvant Trial Organization, Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer: interim analysis at four years. Lancet 1983; 1: 8319
   Google Scholar
• Baum M. And Members of the Nolvadex Adjuvant Trial Organization, Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer: analysis at six years. Lancet 1985; 1: 836
   PubMed Web of Science ®Google Scholar
• Ludwig Breast Cancer Group, Randomized trial of chemoendocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastases. Lancet 1984; 1: 1256
   PubMed Web of Science ®Google Scholar
• Pritchard K. I., Meakin J. W., Boyd N. F., Ambus K., De Boer G., Dembo A. J., Paterson A. H. G., Sutherland D. J. A., Wilkinson R. H., Bassett A. A., Evans W. K., Beale F. A., Clark R. M., Keane T. J. A randomized trial of adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer. Adjuvant Therapy of Cancer IV, S. E. Jones, S. E. Salmon. Grune & Stratton, New York 1984; 339
   Google Scholar
• Rose C., Thorpe S. M., Andersen K. W., Pedersen B. V., Mouridsen H. T., Blicher-Toft M., Rasmussens B. B. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985; 1: 16
   PubMed Web of Science ®Google Scholar
• Wallgren A., Baral E., Carstensen J., Friberg S., Glas U., Hjalmar J.-L., Kargas M., Nordenskjold B., Skoog L., There N.-O., Wilkin N. Should adjuvant tamoxifen be given for several years in breast cancer?. Adjuvant Therapy of Cancer IV, S. E. Jones, S. E. Salmon. Grune & Stratton, New York 1984; 331
   Google Scholar
• Ribeiro G., Palmer M. K. Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute. Br. Med. J. 1983; 286: 827
   PubMed Web of Science ®Google Scholar
• Ribeiro G., Swindell R. The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma—seven-year results. Eur. J. Cancer Clin. Oncol. 1985; 21: 897
   PubMedGoogle Scholar
• Delozier T., Julien J.-P., Juret P., Veyret C., Couette J.-E., Grai Y., Olliver J.-M., de Ranieri E. Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial. Breast Cancer Res. Treat. 1986; 7: 105
   PubMed Web of Science ®Google Scholar
• Stewart H. J., Prescott R. Adjuvant tamoxifen therapy and receptor levels (letter). Lancet 1985; 1: 573
   PubMed Web of Science ®Google Scholar
• Jordan V. C. Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Review of Endocrine-Related Cancer (Oct. Suppl.). ICI, Ltd. Pharmaceuticals Division, MacclesfieldEngland 1978; 49
   Google Scholar
• Jordan V. C., Dix C. J., Allen K. E. The effectiveness of long-term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. Adjuvant Therapy of Cancer IV, S. E. Jones, S. E. Salmon. Grune & Stratton, New York 1979; 19
   Google Scholar
• Jordan V. C. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res. Treaf. 1983; 3: 73, Suppl
   PubMedGoogle Scholar
• Tormey D. C., Jordan V. C. Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res. Treat. 1984; 4: 297
   PubMed Web of Science ®Google Scholar
• Fisher B., Brown A., Wolmark N., Redmond C., Wickerham D. L., Wittliff J. L., Dimitrov N., Legault-Poisson S., Schipper H., Prager D., et al. Prolonging tamoxifen therapy for primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project Clinical Trial. Ann. Intern. Med. 1987; 106: 649
   PubMed Web of Science ®Google Scholar
• Goldhirsch A., Gelber R. D., Mouridsen H. Endocrine aspects in adjuvant therapy for early breast cancer Endocrine Therapy of Breast Cancer: Concepts and Strategies. European School of Oncology monograph, F. Cavalli. Springer-Verlag., Heidelberg 1986; 91
   Google Scholar
• Hubay C. A., Gordon N. H., Growe J. P., Guyton S. P., Pearson O. H., Marshall J. S., Mansour E. G., Hermann R. E., Jones J. C., Flynn W. J., Eckert C., Sponzo R. W., Mc Guire W. L., Evans D., et al. Antiestrogen cytotoxic chemotherapy and bacillus Calmet-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up. Surgery 1984; 96: 61
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Brusamolino E., Galagussa P., Rossi A., Brugnatelli L., Brombilla C., De Lena M., Tancini G., Bajetta E., Musumerci R., Veronesi U. Combination chemotherapy as an adjuvant treatment in operative breast cancer. N. Engl. J. Med. 1976; 294: 405
   PubMed Web of Science ®Google Scholar
• Tormey D. C., Gray R., Taylor S. G., IV, Knuiman M., Olson J. E., Cummings F. J. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer. Natl. Cancer Inst. Monogr. 1986; 1: 75
   Google Scholar
• Fisher B., et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N. Engl. J. Med. 1981; 305: 1
   PubMed Web of Science ®Google Scholar
• Fisher B., Redmond C., Brown A., Wickerham D. L., Wolmark N., Allegra J., Escher G., Lippman M. E., Savlov E., Wittliff J. L., Fisher E. R., et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J. Clin. Oncol. 1983; 1: 227
   PubMed Web of Science ®Google Scholar
• Fisher B., Redmond C., Brown A., Fisher E. R., Wolmark N., Bowman D., Plotkin D., Wolter J., Bornstein R., Legault-Poisson S., Saffer E. A., et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J. Clin. Oncol. 1986; 4: 459
   PubMed Web of Science ®Google Scholar
• Fisher B., Redmond C., Fisher E. R., Wolmark N. Systemic adjuvant therapy in the treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Experience. Natl. Cancer Inst. Monogr. 1986; 1: 35
   Google Scholar
• Padmanabhan N., Howell A., Rubens R. D. Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet 1986; 2: 411
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Rossi A., Tancini G., Valagussa P. Adjuvant chemotherapy in breast cancer. Lancet 1983; 1: 1157
   Google Scholar
• Fisher B., Carbone P. P., Economou S. G., Frelick R., Glass A., Lerner H., Redmond C., Zelen M., Band P., Kataryck D. L., Wolmark N., Fisher E. R. L-Phenylalanine mustard (LPAM) in the management of primary breast cancer: a report of early findings. N. Engl. J. Med. 1975; 292: 117
   PubMed Web of Science ®Google Scholar
• Koyama H., Wada T., Nishizawa Y., Iwanaga T., Aoki Y., Terasawa T., Kosaki G., Yamamoto T., Wada A. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977; 39: 1403
   PubMed Web of Science ®Google Scholar
• Rose D. P., Davis T. E. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet 1977; 1: 1174
   PubMed Web of Science ®Google Scholar
• Samaam N. A., De Asio D. N., Buzdar A. U., Bhmenschein G. R. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer 1978; 41: 2084
   Google Scholar
• Sherman B. M., Wallace R. B., Jochimsen P. R. Hormonal regulation of the menstrual cycle in women with breast cancer: effect of adjuvant chemotherapy. Clin. Endocrinol. 1979; 10: 287
   Google Scholar
• Rose D. P., Davis T. E. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res. 1980; 40: 4043
   PubMed Web of Science ®Google Scholar
• Schilsky R. L., Sherins R. J., Hubbard S. M., Wesley M. N., Young R. C., De Vita V. T. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am. J. Med. 1981; 71: 552
   PubMed Web of Science ®Google Scholar
• Dnistrian A. M., Schwartz M. K., Fracchia A. A., Kaufman R. J., Hakes T. B., Currie V. E. Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer 1983; 51: 803
   PubMedGoogle Scholar
• Jordan V. C., Fritz N. F., Tormey D. C. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res. 1987; 47: 624
   PubMed Web of Science ®Google Scholar
• Ludwig Breast Cancer Study Group, Adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in 1 to 3 axillary lymph nodes: a randomized trial. Cancer Res. 1985; 45: 4454
   PubMed Web of Science ®Google Scholar
• Cole M. P. A clinical trial of an artificial menopausal in carcinoma of the breast. INSERM 1975; 55: 143
   Google Scholar
• Meakin J. W., Allt W. E. C., Beale F. A., Bush R. S., Clark R. M., Fitzpatrick P. J., Hawkins N. V., Jenkin R. D. T., Pringle J. F., Reid J. G., Rider W. D., Hayward J. L., Bulbrook R. D. Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Res. Treat. 1983; 3: 45
   Google Scholar
• Bryant A. J., Weir J. A. Prophylactic oophorectomy in operable instances of carcinoma of the breast. Surg. Gynecol. Obstet. 1981; 153: 660
   PubMedGoogle Scholar
• Ravdin R. G., Lewison E. F., Slack N. H., Gardner B., State D., Fisher B. Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma. Surg. Gynecol. Obstet. 1970; 131: 1055
   PubMedGoogle Scholar
• Tengrup I., Nittby L. T., Landberg T. Prophylactic oophorectomy in the treatment of carcinoma of the breast. Surg. Gynecol. Obstet. 1986; 162: 209
   PubMedGoogle Scholar
• Ludwig Breast Cancer Study Group, Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J. Clin. Oncol. 1985; 3: 1059
   Google Scholar
• Mc Guire W. L., Carbone P. P., Sears M. E., Escher G. C. Estrogen receptors in human breast cancer: an overview. Estrogen Receptors in Human Breast Cancer, W. L. Mc Guire, P. P. Carbone, E. P. Vollmer. Raven Press, New York 1975; 1
   Google Scholar
• Legha S. S., Carter S. K. Antiestrogens in the treatment of breast cancer. Cancer Treat. Rev. 1976; 3: 205
   PubMedGoogle Scholar
• Patterson J. S., Edwards D. G., Battersby L. A. A review of the international clinical experience with tamoxifen. Jpn. J. Cancer Clin. 1981; November: 157, Suppl.
   Google Scholar
• Feil P. D., Glasser S. R., Ton D. O., O'Malley D. W. Progesterone binding in the mouse and rat uterus. Endocrinology 1972; 91: 738
   PubMed Web of Science ®Google Scholar
• Faber L. E., Sandman M. L., Stavely H. E. Progesterone-binding proteins of rat and rabbit uteri. J. Biol. Chem. 1972; 247: 5648
   PubMedGoogle Scholar
• Rao B. R., Wiest W. G., Allen W. B. Progesterone receptor in rabbit uterus. I. Characterization and estradiol-17β augmentation. Endocrinology 1973; 92: 1229
   PubMed Web of Science ®Google Scholar
• Milgrom E., Thi L., Atger M., Baulieu E. E. Mechanism regulating the concentration and conformation of progesterone receptor(s) in the uterus. J. Biol. Chem. 1973; 248: 6366
   PubMed Web of Science ®Google Scholar
• Horwitz K. B., Mc Guire W. L., Pearson O. H., Segaloff A. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975; 189: 726
   PubMed Web of Science ®Google Scholar
• Clark G. M., Mc Guire W. L. Progesterone receptors and human breast cancer. Breast Cancer Res. Treat. 1983; 3: 157
   PubMed Web of Science ®Google Scholar
• Matsumoto K., Ochi H., Nomura Y., Takatoni O., Izuo M., Okamoto R., Sugano H. Progesterone and estrogen receptors in Japanese breast cancer. Hormones, Receptors and Breast Cancer, W. L. Mc Guire. Raven Press, New York 1978; 43
   Google Scholar
• Degenshein G. A., Bloom N., Tobin E. The value of progesterone receptor assays in the management of advanced breast cancer. Cancer 1980; 46: 2789
   PubMed Web of Science ®Google Scholar
• Young P. C. M., Ehrlich C. E., Einhorn L. H. Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer. Cancer 1980; 46: 2961
   Google Scholar
• Brooks S. C., Saunders D. E., Singhakowinta A., Vaitbevicius V. K. Relation of tumor content of estrogen and progesterone receptors with response of patients to endocrine therapy. Cancer 1980; 46: 2775
   Google Scholar
• Manni A., Arafah B., Pearson O. H. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy. Cancer 1980; 46: 2838
   Google Scholar
• Mc Carty K. S., Jr., Cox C., Silva J. S., Woodard B. H., Mossler J. A., Haagensen D. E., Jr., Barton T. K., Mc Carty K. S., Sr., Wells S. A., Jr. Comparison of sex steroid receptor analyses and carcino-embryonic antigen with clinical response to hormone therapy. Cancer 1980; 46: 2846
   Google Scholar
• Nomura Y., Yamagata J., Takenaka K., Tashiro H. Steroid hormone receptors and clinical usefulness in human breast cancer. Cancer 1980; 46: 2880
   Google Scholar
• Skinner L. G., Branes D. M., Ribeiro G. The clinical value of multiple steroid receptor assays in breast cancer management. Cancer 1980; 46: 2939
   Google Scholar
• Bloom N. D., Tobin E. H., Schreibman B., Degenshein G. A. The role of progesterone receptors in the management of advanced breast cancer. Cancer 1980; 46: 2992
   Google Scholar
• Holdaway I. M., Skinner S. J. M. Predicting treatment response in breast cancer using urinary discriminant ratio and receptor assay. Eur. J. Cancer Clin. Oncol. 1981; 17: 1295
   Google Scholar
• Johnson P. A., Bonomi S. G., Anderson K. M., Wolter J. M., Rossof A. H., Economou S. G. Megestrol acetate in advanced breast cancer: response rate related to estrogen receptor and progesterone receptor levels. Proc. Am. Soc. Clin. Oncol. 1982; 1: 89
   Google Scholar
• Lippman M. E., Allegra J. C., Thompson E. B. Lack of estrogen receptor is associated with an increased response rate to cytotoxic chemotherapy in metastatic breast cancer. N. Engl. J. Med. 1978; 298: 1223
   PubMed Web of Science ®Google Scholar
• Allegra J. C., Lippman M. E., Thompson E. B., Simon R., Barlock A., Green L., Huff K. K., Do H. M. T., Aitkin S. C., Warren R. Association between steroid hormone receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. Cancer Treat. Rep. 1978; 62: 1281
   PubMedGoogle Scholar
• Kiang D. T., Frenning D. H., Goldman A. I., Ascensao V. F., Kennedy B. J. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N. Engl. J. Med. 1978; 299: 1330
   PubMedGoogle Scholar
• De Sombre E. R., Carbone P. P., Jensen E. V., Mc Guire W. L., Wells S. A., Wittliff J. L., Lipsett M. B. Steroid receptors in breast cancer. N. Engl. J. Med. 1979; 301: 1011
   PubMedGoogle Scholar
• Carbone P. P., Bauer M., Band P. Chemotherapy of disseminated breast cancer: current status and prospects. Cancer 1977; 39: 2916
   PubMed Web of Science ®Google Scholar
• Waseda N., Kato Y., Imura H., Kurata M. Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer. Cancer Res. 1981; 41: 1984
   PubMed Web of Science ®Google Scholar
• Allegra J. C., Barlock A., Huff K. K., Lippman M. E. Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer 1980; 45: 792
   PubMed Web of Science ®Google Scholar
• Namer M., Lalanne C., Baulieu E. E. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. Cancer Res. 1980; 40: 1750
   PubMed Web of Science ®Google Scholar
• Bressot N., Veith F., Saussol J., Pujol H., Lavie M., Granier M., Gary-Bobo J., Rochefort H. Presurgical radiotherapy decreases the concentrations of estrogen and progesterone receptors in human breast cancer: a 200-patient study. Breast Cancer Res. Treat. 1982; 2: 177
   Google Scholar
• Nomura Y., Tashiro H., Shinozuka K. Changes of steroid receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer. Cancer 1985; 55: 546
   PubMed Web of Science ®Google Scholar
• Smith I. E., Harris A. L., Stuart-Harris R., Ford H. T., Gazet J.-C., White H., Harmer C. L., Carr L., Mc Kinna J. A., Morgan M. Combination treatment with tamoxifen and aminoglutethimide in advanced breast cancer. Br. Med. J. 1983; 286: 1615
   Google Scholar
• Berry J., Green B. J., Matheson D. S. Modulation of natural killer cell activity by tamoxifen in stage I postmenopausal breast cancer. Eur. J. Cancer Clin Oncol. 1987; 22: 517
   Google Scholar
• Welsch C. W. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res. 1985; 45: 3415
   PubMed Web of Science ®Google Scholar
• Bonadonna G. Milan Adjuvant Trials for stage I-II breast cancer. Program and Abstr. 5th Conf. Adjuvant Therapy of Cancer, Tucson, Arizona March 11 to 14, 1987; 37, Abstr.
   Google Scholar
• Williams C. J., Buchanan R. B., Hall V., Taylor I., Cooke T., Nicholson R. I., Griffiths K. Adjuvant chemotherapy (AC) for T1–2, No, Mo estrogen receptor (ER) negative breast cancer preliminary results of a randomized trial. Program and Abstr. 5th Int. Conf. Adjuvant Therapy of Cancer, Tucson, Arizona March 11 to 14, 1987; 38, Abstr.
   Google Scholar
• Jakesz R., Kolb R., Reiner C., Schemper M., Rainer H., Dittrich Ch. Adjuvant chemotherapy in node-negative breast cancer patients. Program and Abstr. 5th Int. Conf. Adjuvant Therapy of Cancer, Tucson, Arizona March 11 to 14, 1987; 39, Abstr.
   Google Scholar
• Dalton W. S., Brooks R. J., Jones S. E., Salmon S. E., Ketchel S. J., Giordano G. F., Jackson R. A., Mosley K., Slyman D. University of Arizona adjuvant breast cancer trials for node negative and node positive patients. Program and Abstr. 5th Int. Conf. Adjuvant Therapy of Cancer, Tucson, Arizona March 11 to 14, 1987; 40, Abstr.
   Google Scholar
• Ciocca D. R., Adam D. J., Edwards D. P., Bjercke R. J., Mc Guire W. L. Distribution of an estrogen-induced protein with a molecular weight of 24,000 in normal and malignant human tissues and cells. Cancer Res. 1983; 43: 1204
   PubMed Web of Science ®Google Scholar
• Edwards D. P., Grzyb K. T., Dressler L. G., Mansel R. E., Zava D. T., Sledge G. W., McGuire W. L. Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res. 1986; 46: 1306
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., Mc Guire W. L. Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177
   PubMed Web of Science ®Google Scholar
• Hand P. H., Nuti M., Colcher D., Schlom J. Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens. Cancer Res. 1983; 43: 728
   PubMed Web of Science ®Google Scholar
• Colcher D., Zalutsky M., Kaplan W., Kufe D., Austin F., Schlom J. Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. Cancer Res. 1983; 43: 736
   PubMed Web of Science ®Google Scholar
• Mènard S., Tagliabue E., Canevari S., Fossati G., Colnaghi M. I. Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. Cancer Res. 1983; 43: 1295
   PubMed Web of Science ®Google Scholar
• Canevari S., Fossati G., Balsari A., Sonnino S., Colnaghi M. I. Immunochemical analysis of the determinant recognized by a monoclonal antibody (MBrl) which specifically binds to human mammary epithelial cells. Cancer Res. 1983; 43: 1301
   PubMed Web of Science ®Google Scholar
• Crogham G. A., Papsidero L. D., Valenzuela L. A., Nernoto T., Penetrante R., Chu T. M. Tissue distribution of an epithelial and tumor-associated antigen recognized by monoclonal antibody F36/22. Cancer Res. 1983; 43: 4980
   Google Scholar
• Iman A., Drustella M. M., Taylor C. R., Tökes Z. A. Generation and immunohistological characterization of human monoclonal antibodies to mammary carcinoma cells. Cancer Res. 1985; 45: 263
   Google Scholar
• Hendler F. J., Yuam D. Relationship of monoclonal antibody binding to estrogen and progesterone receptor content of breast cancer. Cancer Res. 1985; 45: 421
   PubMed Web of Science ®Google Scholar
• Bjorn M. J., Ring D., Frankel A. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res. 1985; 45: 1214
   PubMed Web of Science ®Google Scholar
• Jordan V. C., et al, unpublished data
   Google Scholar